MedTrace Logo

Oral Corticosteroids for Post-infectious Cough in Adults

NCT04232449 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2024-07-03

No results posted yet for this study

Summary

The purpose of this study is to assess whether a 5-day treatment with orally administered prednisone provides patient-relevant benefits by improving the cough-related QoL of patients with post-infectious cough triggered by an Upper Respiratory Tract Infection (URTI) and seeking care in adult primary care practices. The study aims to describe an efficacy and safety profile for a 5-day prednisone treatment compared to a 5-day course of placebo.

Conditions

  • Post-infectious Cough

Interventions

DRUG

PREDNISON Galepharm Tabl. 20 mg

5 daily- doses of 40 mg (2 tablets of 20 mg) of prednisone

DRUG

placebo tablets

5 daily- doses of placebo (2 tablets)

Sponsors & Collaborators

  • Swiss National Science Foundation

    collaborator OTHER

  • University Hospital, Basel, Switzerland

    lead OTHER

Principal Investigators

  • Andreas Zeller, Prof. Dr. med · Centre for Primary Health Care (uniham-bb); University of Basel

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-06
Primary Completion
2024-04-30
Completion
2024-04-30

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04232449 on ClinicalTrials.gov